



## Zinbryta<sup>®</sup> (daclizumab) – Drug withdrawal

- On March 2, 2018, [Biogen and AbbVie announced](#) the voluntary worldwide withdrawal of marketing authorizations for [Zinbryta \(daclizumab\)](#) due to the nature and complexity of adverse events being reported with Zinbryta use.
  - Zinbryta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
- Biogen and AbbVie have determined that the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated.
  - The [European Medicines Agency](#) has received reports of inflammatory encephalitis and meningoencephalitis associated with Zinbryta use.
  - In the U.S., a Risk Evaluation and Mitigation Strategy (REMS) program is in place for Zinbryta due to the risks of severe and fatal hepatic injury including autoimmune hepatitis, and other immune-mediated disorders.
- Biogen will continue to work collaboratively with regulatory authorities and with healthcare providers in their management of Zinbryta patients.
- Patients currently treated with Zinbryta should contact their healthcare provider if they have any questions or concerns regarding their Zinbryta therapy.
- Biogen and AbbVie notified healthcare providers of the drug withdrawal of Zinbryta and advised them to transition patients currently taking Zinbryta to another alternative therapy.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.